

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 234 833 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

28.08.2002 Bulletin 2002/35

(51) Int Cl.7: **C07H 17/08**

(21) Application number: **01204550.6**

(22) Date of filing: **23.02.2000**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: **26.11.1999 ES 9902620**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:

00500028.6 / 1 103 558

(71) Applicant: **Astur-Pharma, S.A.**
28033 Madrid (ES)

(72) Inventors:

- **Bayod Jasanada, Miguel Santos**
(ES)
- **Llorente Garcia, Isidro**
(ES)
- **Fernandez Mari, Félix**
28033 Madrid (ES)

(74) Representative: **Isern Jara, Nuria**
Avda. Diagonal, 463 Bis 2
08036 Barcelona (ES)

Remarks:

This application was filed on 26 - 11 - 2001 as a
divisional application to the application mentioned
under INID code 62.


(54) **Preparation of crystalline azithromycin dihydrate.**

(57) The present invention describes a new procedure for the preparation of the macrolide azithromycin in its crystalline dihydrate form, which is characterized and clearly differentiated by means of the following methods and techniques:

1. IR Spectroscopy.
2. Differential Scan Calorimetry (DSC).
3. X-Ray Diffraction.

Figure 4

Crystalline Azithromycin dihydrate



BEST AVAILABLE COPY

EP 1 234 833 A2

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention.

[0001] Azithromycin is the USAN generic name of the azalide 9-deoxy-9a-aza-9a-methyl-9a-homoerythromycin A, which systematic name is 1-oxa-6-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-C-methyl-1-3-O-methyl-alpha-L-ribo-hexopyranosyl)-oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethyl-amino)-beta-D-xylo-hexopyranosyl)oxy). It is a semisynthetic macrolide that shows an excellent antimicrobial activity against gram-positive and some cases of gram-negative bacteria (H.A. Kirst, G.D. Sides, *Antimicrob. Agents. Chemother.* **1989**, 33, 1419-1422). Clinical use of this macrolide is broadening its application to the treatment of opportunistic infections (F. Lecomte, *Rev. Med. Interne* **1998**, 19(4), 255-61; S. Alvarez-Elcoro, *Mayo Clin. Proc.* **1999**, 74(6), 613-34; J. Schater, *Lancet*, **1999**, 354(9179), 630-35).

2. Description of the Prior Art.

[0002] Figure 1 shows the different synthetic routes to azithromycin 1. The names of the intermediates displayed in Figure 1 are gathered in the following table.

Intermediate	Name
<u>1</u>	Azithromycin
<u>2</u>	Erythromycin A oxime
<u>3</u>	6,9-iminoether
<u>4</u>	9,11-iminoether
<u>5</u>	Azaerythromycin A
<u>6</u>	Azaerythromycin 11,12-hydrogenorthoborate
<u>7</u>	Azithromycin 11,12-hydrogenorthoborate

[0003] The following table summarizes the patents, articles, authors and applicants that describe the different synthetic paths (A, B, C, D, E) towards azithromycin 1.

Route	Patents	Articles	Author	Applicant
A	a) US 4,328,334 • US 4,517,359	• <i>J. Chem. Sac. Perkin Trans 1</i> , 1986 , 1881 • <i>J. Chem. Res.</i> , 1988 , 132 • <i>Idem miniprint.</i> , 1988 , 1239	S. Djokic	PLIVA
B	b) US 4,474,768		G.M. Bright	PFIZER
C	c) US 5,686,587 d) EP 0,699,207		B.V. Yang	PFIZER
D	e) ES 2,104,386 f) US 5,869,629 g) EP 0,827,965	• <i>J.Org.Chem</i> , 1997 , 62, (21), 7479-7481	M. Bayod	ASTUR PHARMA
E	h) ES 2,122,905 i) EP 0,879,823	• <i>Magn. Reson Chem</i> , 1998 , 36, 217-225	W. Heggie	HOVIONE

[0004] The structural elucidation studies carried out with azithromycin 1 have shown the existence of two different crystalline forms: hygroscopic monohydrate and non-hygroscopic dihydrate, being the latter preferred for manufacturing formulations used in therapeutical treatments, as it is described in EP 0,298,650.

Azithromycin dihydrate is easily distinguishable from hygroscopic azithromycin by means of the following differentiative assays:

- a) The dihydrate form keeps its percentile water content constant at values (4.5-5%) which are very close to the

theoretical value (4.6%).

b) The differential calorimetry analysis (DSC) of azithromycin dihydrate reveals the presence of a single endotherm which may vary between 115 and 135 °C, with an energy absorbed during the process which ranges from 27 to 34 cal/g.

c) Each crystalline form presents its own characteristic X-Ray Diffraction spectrum.

d) The infrared spectra in KBr of both crystalline forms present clear differences:

azithromycin dihydrate	azithromycin monohydrate
$\nu(\text{cm}^{-1})$	$\nu(\text{cm}^{-1})$
3560 and 3496 (2 sharp bands)	3500 (wide band)
1344	Does not present any
1282 and 1268 (2 sharp bands)	1280
1083	Does not present any

[0005] Two other synthesis, affording azithromycin 1 as a form that should differ from the crystalline ones previously mentioned, have also been described. In these cases, azithromycin is obtained by simple evaporation to dryness. However, in these documents there is no reference to the crystalline state of the azithromycin thus obtained.

Patent	Applicant (Author)	Priority	Procedure
• WO 94/26758 a) US 5,686,587 b) EP 0,699,207 c) ES 2,104,386	PFIZER (B.V. Yang)	May 19, 1993	Methylene chloride evaporation
• BE 892,357 • US 4,517,359	PLIVA (S. Djokic)	Mar. 3, 1981	Chloroform evaporation

[0006] In the following table are summarized the different procedures for the preparation of both crystalline forms of azithromycin 1.

Crystalline form	Patent	Applicant (Author)	Priority	Procedure
HYGROSCOPIC MONOHYDRATE	a) EP 0,101,186 b) US 4,474,768	PFIZER (G.M. Bright)	July 19, 1982	Recrystallization from ethanol/water
HYGROSCOPIC MONOHYDRATE	c) EP 0,298,650	PFIZER (D. Allen)	July 9, 1997	Recrystallization from ethanol/water
NON-HYGROSCOPIC DIHYDRATE	d) EP 0,298,650 e) WO 89/00576 f) ES 2,038,756	PFIZER (D. Allen)	July 9, 1997	Recrystallization from THF / petroleum ether/water • Recrystallization from acetone/water
NON-HYGROSCOPIC DIHYDRATE	g) CN 1,093,370 (Chem. Abs. 29525q,124,1996)	Eaming Zhuanli.... (Q. Song)	Dec. 10, 1993	• Recrystallization from other solvents (methanol, DMF, acetonitrile, dioxane, ...) and water
NON-HYGROSCOPIC DIHYDRATE	h) EC 95-1389	CHEMO-TECNICA SINTYAL	May, 1995	Recrystallization from acetone/water

(continued)

Crystalline form	Patent	Applicant (Author)	Priority	Procedure
NON-HYGROSCOPIC DIHYDRATE	i) EP 0,827,965 j) ES 2,122,905 k) US 5,869,629	ASTUR PHARMA (M.Bayod)	July 11, 1996	Recrystallization from acetone/ water
NON-HYGROSCOPIC DIHYDRATE	l) EP 0,941,999	HOVIONE (W.Heggie)	Mar 13, 1998	Precipitation from a base neutralized acid solution of azithromycin in acetone/water
Crystalline form	Article	Author	Date	Procedure
NON-HYGROSCOPIC DIHYDRATE	· <i>J. Chem. Res.</i> , 1988, 132 m) <i>idem</i> <i>miniprint.</i> , 1988, 1239,	S.Djokic (PLIVA)	May, 1988 (received June 4, 1987)	Two recrystallizations: 1. Precipitation from a base neutralized acid solution of azithromycin in acetone/ water. 2. From ethyl ether.
NON-HYGROSCOPIC DIHYDRATE	· <i>J. Org. Chem.</i> , 1997, 62, (21), 7479-7481	M.Bayod (ASTUR-PHARMA)	Nov., 1997 (received May 1, 1997)	Recrystallization from acetone/water
HYGROSCOPIC MONOHYDRATE	· <i>J. Org. Chem.</i> , 1997, 62, (21), 7479-7481	M.Bayod (ASTUR PHARMA)	Nov., 1997 (received May 1, 1997)	Recrystallization from ethanol/water

DESCRIPTION OF THE INVENTION.

[0007] The present invention provides a series of new procedures for the preparation of azithromycin 1:

- A procedure for the preparation of its crystalline dihydrate form, characterized by crystallization of azithromycin from a mixture of *tert*-butanol / water. In this procedure crystalline azithromycin monohydrate is dissolved in *tert*-butanol and, after water addition, is allowed to crystallize for a period of 48-72 hours.
- A procedure for the preparation of its crystalline dihydrate form, characterized by crystallization of azithromycin from a mixture of *tert*-butanol / petroleum ether / water. In this procedure, crystalline azithromycin monohydrate is dissolved in *tert*-butanol and added to a mixture of petroleum ether and water. This solution is allowed to crystallize for a period of 48-72 hours.

[0008] The procedures that are the object of the present invention are advantageous over previously described methods, essentially at industrial scale because these crystallization procedures, which are characterized by slow crystal growth, greatly improve the homogeneity and particle distribution of different batches. This minimizes the presence of the non-crystalline fraction (detected by X-Ray and DSC) that is always present in crystalline azithromycin dihydrate obtained by the methods reported in the literature and above cited.

[0009] Crystalline azithromycin dihydrate is unequivocally characterized by means of its IR (Fig. 2) and X-Ray Diffraction (Fig. 4) spectra and DSC thermogram (Fig. 3).

EXPERIMENTAL PART

- Preparation of 9-deoxo-9a-aza-11,12-desoxy-9a-homoerythromycin A 11,12-hydrogenorthoborate.

[0010] 89 g of 9-deoxo-6-desoxy-6,9-epoxy-9,9a-dihydro-9a-aza-homoerythromycin A are dissolved in 450 ml of methanol and cooled down between -5° and -10 °C. While keeping the temperature in the specified interval 16 portions of 2.2 g each of sodium borohydride are added. Temperature and stirring conditions are maintained for two additional

hours and the bulk of the reaction is allowed to reach 20 °C. After 20 h, the methanol is evaporated to dryness. The residue is dissolved in 500 ml of methylene chloride and 750 ml of water and shaken for 30 min. The organic phase is separated and the aqueous phase is extracted with 250 ml of methylene chloride. The organic phases are combined, filtered over celite, dried with anhydrous sodium sulphate and concentrated to dryness to yield 85 g of 9-deoxy-9a-aza-11,12-desoxy-9a-homoerythromycin A 11,12-hydrogenorthoborate.

IR (KBr)	$\nu_{\max} = 3500, 2980, 2960, 1730, 1470, 1390, 1170, 1090, 1060 \text{ cm}^{-1}$
$^1\text{H-NMR}$ (CDCl_3) (partial)	$\delta = 2.21 (\text{NMe}_2), 3.27 (\text{OMe}) \text{ ppm}$
$^{13}\text{C-NMR}$ (CDCl_3) (partial)	$\delta = 180.0 (\text{C=O}), 79.63 (\text{C}_{11}), 76.46 (\text{C}_{12}), 58.7 (\text{C}_{10}), 57.1 (\text{C}_9), 49.4 (\text{OMe}), 40.2 (\text{NMe}_2) \text{ ppm}$
$^{11}\text{B-NMR}$ (CDCl_3)	$\delta = 9.9 \text{ ppm} \quad \omega_{\frac{1}{2}} = 200 \text{ Hz}$
TLC	$r_f = 0.28$ (petroleum ether: ethyl acetate: diethylamine 75:25:10) developer: ethanol/vanillin (sulphuric acid)

• **Preparation of 9-deoxy-9a-aza-11,12-desoxy-9a-methyl-9a-homo-erythromycin A 11,12-hydrogenorthoborate.**

[0011] 50 g of 9-deoxy-9a-aza-11,12-desoxy-9a-homoerythromycin A 11,12-hydrogenorthoborate are dissolved in 500 ml of chloroform, and subsequently a mixture of 5.5 ml of formic acid and 11.75 ml of aqueous 35-40% formaldehyde is added. The reaction mixture is heated under pressure for 14 hours and subsequently cooled down to 15-20°C. 500 ml of water are added and the mixture is taken to pH=4 by adding 20% sulphuric acid. The mixture is shaken for 15 min and the lower organic layer is separated. The alkaline aqueous phase is extracted with 2x100 ml methylene chloride. The organic phases are combined and filtered over celite, dried with anhydrous sodium sulfate and evaporated to dryness. The residue obtained is washed twice with 250 ml of ethyl ether, yielding a dry residue of 29 g of 9-deoxy-9a-aza-11,12-desoxy-9a-methyl-9a-homo-erythromycin A 11,12-hydrogenorthoborate.

IR (KBr)	$\nu_{\max} = 3500, 1730, 1470, 1390, 1090, 1070 \text{ cm}^{-1}$
$^1\text{H-NMR}$ (CDCl_3) (partial)	$\delta = 2.00 (\text{NMe}_2), 2.30 (\text{NMe}), 3.37 (\text{OMe}) \text{ ppm}$
$^{13}\text{C-NMR}$ (CDCl_3) (partial)	$\delta = 179.9 (\text{C=O}), 79.40 (\text{C}_{11}), 77.09 (\text{C}_{12}), 68.84 (\text{C}_9), 64.08 (\text{C}_{10}), 49.36 (\text{OMe}), 40.18 (\text{NMe}_2), 34.39 (\text{NMe}) \text{ ppm}$
$^{11}\text{B-NMR}$ (CDCl_3)	$\delta = 10.1 \text{ ppm} \quad \omega_{\frac{1}{2}} = 180 \text{ Hz}$
m/e	$M^+ = 775.5$
TLC	$r_f = 0.38$ (petroleum ether: ethyl acetate: diethylamine 75:25:10) developer: ethanol/vanillin (sulphuric acid)

• **Hydrolysis of 9-deoxy-9a-aza-11,12-desoxy-9a-methyl-9a-homo-erythromycin A 11,12-hydrogenorthoborate. Synthesis of 9-deoxy-9a-aza-9a-methyl-9a-homo-erythromycin A (Azithromycin).**

[0012] 22 g of 9-deoxy-9a-aza-11,12-desoxy-9a-methyl-9a-homo-erythromycin A 11,12-hydrogenorthoborate are dissolved in 250 ml of acetonitrile to which 125 ml of water are subsequently added. 20% sulphuric acid is added to the mixture to take it to pH=2, and stirring is maintained for 30 min. The acidic solution is poured into a mixture of 350 ml of methylene chloride and 350 ml of water, immediately adding 48% lime until pH=9. The mixture is shaken for 15 min and the lower organic phase is separated. The alkaline aqueous phase is extracted with 2x100 ml of methylene chloride. The combined organic phases are filtered over celite and evaporated to dryness. The residue is dissolved in 50 ml of ethanol and 60 ml of water are added over 30 min. Precipitation is allowed for 2 h, and the solid is collected by filtration and vacuum-dried at 40°C to yield 15 g of 9-deoxy-9a-aza-9a-methyl-9a-homo-erythromycin A (Azithromycin).

IR (KBr)	$\nu_{\max} = 3500, 3000, 2970, 1740, 1470, 1380, 1280, 1060 \text{ cm}^{-1}$
$^1\text{H-NMR}$ (CDCl_3) (partial)	$\delta = 2.31 (\text{NMe}_2), 2.34 (\text{NMe}), 3.38 (\text{OMe}) \text{ ppm}$
$^{13}\text{C-NMR}$ (CDCl_3) (partial)	$\delta = 178.9 (\text{C=O}), 73.08 (\text{C}_{12}), 72.32 (\text{C}_{11}), 69.88 (\text{C}_9), 62.43 (\text{C}_{10}), 49.37 (\text{OMe}), 40.23 (\text{NMe}_2), 35.92 (\text{NMe}) \text{ ppm}$

(continued)

m/e	M ⁺ = 749.5
HPLC	corresponds according to <i>USP XXIII</i>
TLC	rf = 0.62 (petroleum ether : ethyl acetate : diethylamine 75:25:10) developer: ethanol/vanillin (sulphuric acid)

• **Preparation of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate. Method A.**

[0013] 25 g of crystalline azithromycin monohydrate are dissolved in 130 ml of *tert*-butanol heating at 30°C. This solution is filtered and 130 ml of water are added over 6 h. The resulting mixture is taken to pH=11 by addition of NaOH 2N, cooled down below 10°C and subsequently stirred for 48-72 h. The crystals are collected by filtration and dried (80 mm Hg / 25°C) to yield 15 g of azithromycin dihydrate.

IR (KBr) ν_{\max} = 3560, 3496, 1740, 1470, 1380, 1344, 1282, 1268, 1251, 1093 cm⁻¹ ¹H-NMR (CDCl₃), ¹³C-NMR (CDCl₃), m/e, TLC and HPLC are identical to those of the previous example.

• **Preparation of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate. Method B.**

[0014] 25 g of crystalline azithromycin monohydrate are dissolved in 50 ml of *tert*-butanol heating at 30°C. This solution is filtered and discharged over a mixture of 500 ml of petroleum ether and 20 ml of water. The resulting mixture is cooled down below 10°C and subsequently stirred for 48-72 h. The crystals are collected by filtration and dried (80 mm Hg / 25 °C) to yield 12 g of azithromycin dihydrate.

IR (KBr), ¹H-NMR (CDCl₃), ¹³C-NMR (CDCl₃), m/e, TLC and HPLC are identical to those of the previous example.

Claims

1. A process for the preparation of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A (Azithromycin) in its crystalline dihydrate form **characterized by** crystallization after water addition to a solution of azithromycin in *tert*-butanol.
2. A process for the preparation of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A (Azithromycin) in its crystalline dihydrate form **characterized by** crystallization from a solution of azithromycin in *tert*-butanol by addition over a mixture of petroleum ether and water.
3. A process for the preparation of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A (Azithromycin) in its crystalline dihydrate form **characterized by**:
 - ✓ Hydrolysis of 9-deoxo-9a-aza-11,12-desoxy-9a-methyl-9a-homo-erythromycin A 11,12-hydrogenorthoborate in an organic solvent (ethyl acetate, acetonitrile, methanol or ethanol) by the action of a dilute acid (sulphuric acid, hydrochloric acid, oxalic acid) at room temperature and at a pH range comprised between 2 and 4.
 - ✓ Dissolution of azithromycin in *tert*-butanol.
 - ✓ Crystallization by addition of water.
4. A process for the preparation of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A (Azithromycin) in its crystalline dihydrate form **characterized by**:
 - ✓ Hydrolysis of 9-deoxo-9a-aza-11,12-desoxy-9a-methyl-9a-homo-erythromycin A 11,12-hydrogenorthoborate in an organic solvent (ethyl acetate, acetonitrile, methanol or ethanol) by the action of a dilute acid (sulphuric acid, hydrochloric acid, oxalic acid) at room temperature and at a pH range comprised between 2 and 4.
 - ✓ Dissolution of azithromycin in *tert*-butanol.
 - ✓ Crystallization by addition over a mixture of petroleum ether and water.

Figure 1. Synthesis of Azithromycin




Figure 2

Crystalline Azithromycin Dihydrate






Figure 3**Thermogram of crystalline Azithromycin dihydrate**

Figure 4

Crystalline Azithromycin dihydrate



(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 234 833 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
12.03.2003 Bulletin 2003/11

(51) Int Cl.7: **C07H 17/08**

(43) Date of publication A2:
28.08.2002 Bulletin 2002/35

(21) Application number: **01204550.6**

(22) Date of filing: **23.02.2000**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(72) Inventors:
• **Bayod Jasanada, Miguel Santos**
(ES)
• **Llorente Garcia, Isidro**
(ES)
• **Fernandez Mari, Félix**
28033 Madrid (ES)

(30) Priority: **26.11.1999 ES 9902620**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
00500028.6 / 1 103 558

(74) Representative: **Isern Jara, Nuria**
Avda. Diagonal, 463 Bis 2
08036 Barcelona (ES)

(71) Applicant: **Astur-Pharma, S.A.**
28033 Madrid (ES)


(54) **Preparation of crystalline azithromycin dihydrate.**

(57) The present invention describes a new procedure for the preparation of the macrolide azithromycin in its crystalline dihydrate form, which is characterized and clearly differentiated by means of the following methods and techniques:

1. IR Spectroscopy.
2. Differential Scan Calorimetry (DSC).
3. X-Ray Diffraction.

Figure 4

Crystalline Azithromycin dihydrate



EP 1 234 833 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 20 4550

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	EP 0 827 965 A (ASTUR PHARMA S A) 11 March 1998 (1998-03-11) * abstract, claims 1-7, especially the figure 2 and claim 4 *	1-4	C07H17/08
A	WO 99 58541 A (BIOCHEMIE SA ;DIAGO JOSE (ES); BOSCH IMMACULADA (ES); CENTELLAS VI) 18 November 1999 (1999-11-18) * page 11; example 2; table 1 *	1-4	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C07H
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 14 January 2003	Examiner Scott, J
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.02 (P04C01)

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 01 20 4550

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

14-01-2003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0827965	A	11-03-1998	ES 2122905 A1	16-12-1998
			EP 0827965 A2	11-03-1998
			JP 3101590 B2	23-10-2000
			JP 10072482 A	17-03-1998
			US 5869629 A	09-02-1999
WO 9958541	A	18-11-1999	AU 4139799 A	29-11-1999
			CA 2330007 A1	18-11-1999
			CN 1299368 T	13-06-2001
			WO 9958541 A2	18-11-1999
			EP 1077986 A2	28-02-2001
			HR 20000758 A1	30-06-2001
			JP 2002514653 T	21-05-2002
			US 6420537 B1	16-07-2002

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)